Limited Stage Small Cell Lung Cancer
Conditions
Interventions
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years. 2. Patients with limited-stage SCLC who have a clear pathological diagnosis and have received first-line treatment (standard radiotherapy and chemotherapy regimens). 3. The expected survival time is >= 6 months. 4. The ECOG score of physical strength is 0-2 points. 5. Volunteer to participate in this study and sign an informed consent form. 6. Chemotherapy >= 2 cycles, and the curative effect is evaluated as SD, PR or CR.
Exclusion criteria
Exclusion criteria: 1. Combined with serious diseases such as heart, liver, kidney and hematopoietic system. 2. Patients who are known to be allergic to the study medication. 3. Children, pregnant women, psychiatric patients and patients suffering from other malignant tumors. 4. Patients who are undergoing other drug trials. 5. Patients who have completed lung cancer surgery. 6. Patients whose curative effect is evaluated as PD after chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Neuron-specific enolase, NSE;Physical condition score;Evaluation of TCM symptoms;pro-GRP;Survival after progression;Recurrence and metastasis rate;Life quality evaluation;Imaging evaluation; | — |
Countries
China
Contacts
Public ContactLi Conghuang
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed